Products
Motretinide was commercially available as a cream in many countries and had been approved since 1981 (Tasmaderm). Unlike other topical retinoids such as isotretinoin (Roaccutane) or tretinoin (Retin-A), it was available without a physician’s prescription. It was discontinued in 2015.
Structure and properties
Motretinide (C23H31NO2, Mr = 353.5 g/mol) is an aromatic derivative of the vitamin A acid tretinoin.
Effects
Motretinide (ATC D10AD05) inhibits the formation of new comedones and is anti-inflammatory.
Indications
For the treatment of mild acne and for maintenance therapy after peel treatment has been performed.
Dosage
According to the professional information. The drug is applied to the affected areas of the skin in the morning and evening. If skin redness occurs, it may be reduced to once-daily administration.
Contraindications
Motretinide is contraindicated in hypersensitivity. It should not be used before or during pregnancy because fertility-damaging effects, as with other retinoids, cannot be ruled out. Full precautions can be found in the drug label.
Interactions
No drug-drug interactions have been reported to date.
Adverse effects
Possible adverse effects include transient skin irritation and rarely worsening of the disease.